Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$506.51 USD

506.51
1,041,901

+0.17 (0.03%)

Updated Nov 4, 2024 09:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IQVIA (IQV) Up 3.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now

by Zacks Equity Research

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

Omnicell (OMCL) Introduces Central Med Automation Service

by Zacks Equity Research

Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y

by Zacks Equity Research

Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.

Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed

by Zacks Equity Research

Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.

NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up

by Zacks Equity Research

NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.

Paragon 28 (FNA) Expands SMART 28 Ecosystem With New Launches

by Zacks Equity Research

Paragon 28 (FNA) strengthens its position in the foot and ankle device market with the launch of the SMART28 Case Management Portal and the SMART Bun-Yo-Matic device.

Compelling Reasons to Hold Molina Healthcare (MOH) Stock Now

by Zacks Equity Research

Molina Healthcare (MOH) remains well-poised for growth, attributable to membership growth in Medicaid and Medicare businesses. Buyouts and an adequate cash balance remain other benefits.

Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.

Haemonetics (HAE) Set to Launch VASCADE MVP XL in US

by Zacks Equity Research

Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.

Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US

by Zacks Equity Research

Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.

Is Intuitive Surgical (ISRG) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Intuitive Surgical (ISRG) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX

by Zacks Equity Research

Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.

Sanghamitra Saha headshot

Inflation Cools in July: 4 Sector ETFs & Stocks to Thrive

by Sanghamitra Saha

The annual inflation rate in the United States slowed for a fourth successive month in July 2024.

Labcorp (LH) Gains From New Collaborations Amid FX Issues

by Zacks Equity Research

Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.

Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial

by Zacks Equity Research

Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.

Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook

by Zacks Equity Research

Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.

Can Intuitive Surgical (ISRG) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Intuitive Surgical (ISRG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Quest Diagnostics (DGX) Gains From Innovation, Customer Wins

by Zacks Equity Research

A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.

Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

by Zacks Equity Research

Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.

Here's How Much a $1000 Investment in Intuitive Surgical, Inc. Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View

by Zacks Equity Research

Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.

Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises

by Zacks Equity Research

Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.